Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
Silo Pharma expects to commercially launch its QwikAgents AI platform within the next 60 days, targeting the enterprise automation market to begin generating initial revenue. The company is advancing its lead PTSD therapeutic SPC-15, with a drug-device robustness study set to complete in approximately 60 days to support a Type C FDA meeting request and subsequent IND submission.
Key figures
- Ai launch timeline days
- 60
- Device study completion days
- 60
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.